NMPA (China) approves two dose schedule for HPV vaccine Cervarix for prevention of cervical cancer.- GSK
GSK plc has announced that a two-dose schedule for its HPV vaccine Cervarix [Human Papillomavirus bivalent (types 16, 18) Vaccine, Recombinant)] has been approved by China’s NMPA for girls aged 9 to 14 for prevention of cervical cancer.
With this approval, Cervarix is the first imported two-dose HPV vaccine for this age group in mainland China. The NMPA authorisation of the two-dose regimen adds China to two-dose approvals in approximately 100 countries, including the European Union, Asia, Africa, and Latin America. The three-dose schedule remains on the label for girls and women aged 15-45 years in China.
In 2020, there were approximately 110,000 new cases of cervical cancer and 59,000 deaths due to the disease in China.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.